Can someone tell our head marketer….

[anonymous]

Providers don’t “prescribe” a buy and bill injection that’s administered in office? Novartis doesn’t even speak the language. They will administer, inject, or order it, but they will never prescribe it.

 

[anonymous]

Touche!

In rare company my friend. Someone who likely has dealt w/ B&B before, and knows you don't prescribe it, unless using a Specialty Pharmacy.

 

[anonymous]

Touche!

In rare company my friend. Someone who likely has dealt w/ B&B before, and knows you don't prescribe it, unless using a Specialty Pharmacy.

I’m glad there is at least one other rep at this company with a clue! I’ve never felt so overqualified or under appreciated at my job before. We look like idiots calling this a “prescription” or asking docs to “prescribe” this and I continually hear that language from managers, colleagues, and now even the head marketer. This reorg is good so at least they can figure out who to give credit to for what we are already selling for them. A year late with this and samples, but here we are.
If they make us pay for their idiocy with our jobs I hope they get what’s coming to them.

 

[anonymous]

I’m glad there is at least one other rep at this company with a clue! I’ve never felt so overqualified or under appreciated at my job before. We look like idiots calling this a “prescription” or asking docs to “prescribe” this and I continually hear that language from managers, colleagues, and now even the head marketer. This reorg is good so at least they can figure out who to give credit to for what we are already selling for them. A year late with this and samples, but here we are.
If they make us pay for their idiocy with our jobs I hope they get what’s coming to them.

I'm not looking to pick a fight, but I am confused by something you said. How will this reorg solve the sales credit issues?
They didn't say they're buying data from more AIC's did they? If so, I missed it. I also missed it if they committed to doing a better job of tracking B&B and making the PRISM data at least semi-useful.
Until they fix those issues (still no acknowledgement from senior leadership that the data capture is complete shit) we'll never receive proper credit.

 

[anonymous]

I'm not looking to pick a fight, but I am confused by something you said. How will this reorg solve the sales credit issues?
They didn't say they're buying data from more AIC's did they? If so, I missed it. I also missed it if they committed to doing a better job of tracking B&B and making the PRISM data at least semi-useful.
Until they fix those issues (still no acknowledgement from senior leadership that the data capture is complete shit) we'll never receive proper credit.

Sadly you will most likely never get true credit for all of the business you generate. Ask anyone who works in respiratory. Most of the larger infusions centers purchase out of a main location and unless they are set specifically set up to ship to individual locations the only person who will get credit is the person whose territory the main center is in. There is a person in respiratory who consistently wins P club because of this issue and it can’t be fixed. Even with smaller specialty pharmacy’s most often they can’t track to the doctor level just to the place where the specialty pharmacy is located. It sucks

 

[anonymous]

Ahh, the joys of Bill To vs Ship To.

 

[anonymous]

I'm not looking to pick a fight, but I am confused by something you said. How will this reorg solve the sales credit issues?
They didn't say they're buying data from more AIC's did they? If so, I missed it. I also missed it if they committed to doing a better job of tracking B&B and making the PRISM data at least semi-useful.
Until they fix those issues (still no acknowledgement from senior leadership that the data capture is complete shit) we'll never receive proper credit.

You are correct on all counts. Except at least now the company won’t be splitting credit between PCP and CV. There is a lot of grey here and every area playing by different rules. At least we will know which reps get credit now in the Leqvio one report.